Preclinical study identifies Rb1 deficiency as key therapeutic vulnerability in a subset of breast cancers resistant to standard CDK4/6 inhibitors Drugs that may exploit this vulnerability are already ...
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.
Hosted on MSN
RB1 identified as predictive biomarker for new therapeutic strategy in some breast cancers
A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results